Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
-, DOCETAXEL , DEXAMETHASONE , -, -, MK-2870, PARACETAMOL, COMBINATIONS EXCL. PSYCHOLEPTICS, PEMETREXED
Merck Sharp and Dohme
Non-small Cell Lung Cancer (NSCLC)
1 trial -
ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, ALIMTA 500 mg powder for concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Pembrolizumab, KEYTRUDA 25 mg/m
Celltrion Healthcare Hungary Kft.
Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer
1 trial -
AVELUMAB, DOSTARLIMAB, ATEZOLIZUMAB, AVELUMAB, CEMIPLIMAB, DOSTARLIMAB, NIVOLUMAB, PEMBROLIZUMAB, NIVOLUMAB, DURVALUMAB, CEMIPLIMAB, ATEZOLIZUMAB, PEMBROLIZUMAB, DURVALUMAB
Cancer Prevention Pharma (Ireland) Limited
Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability [MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer, gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI).
1 trial -
Abraxane 5 mg/ml powder for dispersion for infusion., CISPLATIN , PEMBROLIZUMAB, CARBOPLATIN , PACLITAXEL , PEMETREXED
Fondazione Telethon ETS
metastatic NSCLC patients
1 trial -
CANAKINUMAB, PEMETREXED
Novartis Ophthalmics Europe
Non-small cell lung cancer
1 trial -
CARBOPLATIN, CARBOPLATIN, DS-8201a, PEMETREXED, CISPLATIN, PEMBROLIZUMAB
Daiichi Sankyo Europe GmbH
Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer
1 trial -
CARBOPLATIN, CARBOPLATIN, IPILIMUMAB, PEMETREXED, CISPLATIN, INFLIXIMAB, PEMETREXED, Mycofit, 250 mg, kapsułki twarde, NIVOLUMAB, volrustomig
AstraZeneca AB
Unresectable Pleural Mesothelioma
1 trial -
CARBOPLATIN, CARBOPLATIN, Patritumab deruxtecan, PEMETREXED, CISPLATIN
Daiichi Sankyo Europe GmbH
Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC)
1 trial -
CARBOPLATIN, CISPLATIN, PEGFILGRASTIM, PEMETREXED, BL-B01D1
Bristol-Myers Squibb / Pfizer EEIG
EGFR-mutated Non-small Cell Lung Cancer
1 trial -
CARBOPLATIN, CISPLATIN, PEMBROLIZUMAB, PEMETREXED, DS-8201a, PEMETREXED
AstraZeneca AB
Unresectable, locally advanced, or metastatic Non-Small Cell Lung Cancer with HER2 exon 19 or 20 mutations
1 trial -
CARBOPLATIN, CISPLATIN, PEMETREXED, CARBOPLATIN, PEMETREXED, OSIMERTINIB, CISPLATIN, Telisotuzumab adizutecan, OSIMERTINIB, CARBOPLATIN, PEMETREXED
AbbVie Deutschland GmbH & Co. KG
Non-Squamous Non-Small Cell Lung Cancer
1 trial -
CARBOPLATIN, GEMCITABINE, PEMETREXED, Sindaxel 6 mg/ml concentrat pentru soluţie perfuzabilă, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CISPLATIN, Abraxane 5 mg/ml powder for dispersion for infusion., RO 749-9790/F02-02
Roche Registration Limited
RET fusion−positive, metastatic Non-Small Cell Lung Cancer
1 trial -
CISPLATIN , PACLITAXEL , GEMCITABINE , CARBOPLATIN , placebo for mRNA-4157, PEMETREXED , mRNA-4157, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion
Merck Sharp and Dohme
Non-Small Cell Lung Cancer
1 trial -
CISPLATIN, Armisarte 25 mg/ml concentrate for solution for infusion, CARBOPLATIN, PEMETREXED, TAGRISSO 80 mg film-coated tablets, PLACEBO, TAGRISSO 40 mg film-coated tablets
AstraZeneca AB
Patients with histologically or cytologically documented non-squamous NSCLC with completely resectable (Stage II - IIIB N2) disease
1 trial -
CISPLATIN, CISPLATIN, Telisotuzumab adizutecan, OSIMERTINIB, PEMETREXED, CARBOPLATIN, CISPLATIN, AMIVANTAMAB, AMIVANTAMAB, CARBOPLATIN, CARBOPLATIN, PEMETREXED, OSIMERTINIB, PEMETREXED
AbbVie Deutschland GmbH & Co. KG
Non-Small Cell Lung Cancer
1 trial -
CISPLATIN, TAGRISSO 40 mg film-coated tablets, Datopotamab deruxtecan, TAGRISSO 80 mg film-coated tablets, CARBOPLATIN, PEMETREXED
AstraZeneca AB
Non squamous non-small cell lung cancer (NSCLC)
1 trial -
Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BAY 2927088 Bayer (CM), Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, BAY 2927088, BAY 2927088 Bayer (CM), Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BAY 2927088 Bayer
Bayer AG
Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
1 trial -
Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Zipalertinib, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion
Taiho Pharma Netherlands B.V.
Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
1 trial -
DURVALUMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., CISPLATIN, ETOPOSIDE, Olaparib, CARBOPLATIN, MK-7339, Olaparib Placebo, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, PEMETREXED, PACLITAXEL
Merck Sharp and Dohme
Non-small cell lung cancer
1 trial -
GEMCITABINE , Tecentriq, PEMETREXED , VINORELBINE , CISPLATIN , DOCETAXEL , Tecentriq 1,200 mg concentrate for solution for infusion
Roche Registration Limited
Non−Small Cell Lung Cancer
1 trial -
IMJUDO 20 mg/ml concentrate for solution for infusion., PACLITAXEL SANDOZ 6 mg/ml, solution à diluer pour perfusion, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, CARBOPLATINE KABI 10 mg/ml, solution à diluer pour perfusion, IMFINZI 50 mg/mL concentrate for solution for infusion, Tecentriq 840 mg concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., Cisplatine Accord 1 mg/ml concentraat voor op
Institut für biomedizinische Analytik NMR-Imaging GmbH
Synchronous oligometastatic non-small cell lung cancer (NSCLC)
1 trial -
INFLIXIMAB , MYCOPHENOLIC ACID , SALINE, ETOPOSIDE , CARBOPLATIN , PEMETREXED , IMFINZI 50 mg/mL concentrate for solution for infusion., CISPLATIN , PACLITAXEL
AstraZeneca AB
Patients with Locally Advanced, Unresectable Non-small Cell Lung Cancer (Stage III)
1 trial -
JNJ-61186372, Carboplatin 10 mg/ml Intravenous Infusion, CARBOPLATIN , Pemetrexed Seacross 500 mg powder for concentrate for solution for infusion, PEMETREXED
Janssen-Cilag International N.V.
EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
1 trial -
JNJ-73841937, Pemetrexed Seacross 500 mg powder for concentrate for solution for infusion, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung Carboplatin, JNJ-61186372, CARBOPLATIN , Carboplatin 10 mg/ml Intravenous Infusion, PEMETREXED
Janssen-Cilag International N.V.
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources